Loading [MathJax]/jax/output/SVG/jax.js
Review

Insights on neuroendocrine regulation of immune mediators in female reproductive aging and cancer

  • Neuroendocrine-immune homeostasis in health and disease is a tightly regulated bidirectional network that influences predisposition, onset and progression of age-associated disorders. The complexity of interactions among the nervous, endocrine and immune systems necessitates a complete review of all the likely mechanisms by which each individual system can alter neuroendocrine-immune homeostasis and influence the outcome in age and disease. Dysfunctions in this network with age or external/internal stimuli are implicated in the development of several disorders including autoimmunity and cancer. The existence of sympathetic noradrenergic innervations on lymphoid organs in synaptic association with immune cells that express receptors for endocrine mediators such as hormones, neural mediators such as neurotransmitters and immune effector molecules such as cytokines explains the complicated nature of the regulatory pathways that must always maintain homeostatic equilibrium within and among the nervous, endocrine and immune systems. The incidence, development and progression of cancer, affects each of the three systems by disrupting regulatory pathways and tipping the scales away from homeostasis to favour pathways that enable it to evade, override and thrive by using the network to its advantage. In this review, we have explained how the neuroendocrine-immune network is altered in female reproductive aging and cancer, and how these modulations contribute to incidence and progression of cancer and hence prove to be valuable targets from a therapeutic standpoint. Reproductive aging, stress-associated central pathways, sympathetic immunomodulation in the periphery, inflammatory and immunomodulatory changes in central, peripheral and tumor-microenvironment, and neuro-neoplastic associations are all likely candidates that influence the onset, incidence and progression of cancer.

    Citation: Hannah P. Priyanka, Rahul S. Nair, Sanjana Kumaraguru, Kirtikesav Saravanaraj, Vasantharekha Ramasamy. Insights on neuroendocrine regulation of immune mediators in female reproductive aging and cancer[J]. AIMS Molecular Science, 2021, 8(2): 127-148. doi: 10.3934/molsci.2021010

    Related Papers:

    [1] Oleg Sukharev, Ekaterina Voronchikhina . Financial and non-financial investments: comparative econometric analysis of the impact on economic dynamics. Quantitative Finance and Economics, 2020, 4(3): 382-411. doi: 10.3934/QFE.2020018
    [2] Sandro Claudio Lera, Didier Sornette . Evidence of A Bimodal US GDP Growth Rate Distribution: A Wavelet Approach. Quantitative Finance and Economics, 2017, 1(1): 26-43. doi: 10.3934/QFE.2017.1.26
    [3] Diego Ardila, Ahmed Ahmed, Didier Sornette . Comparing ask and transaction prices in the Swiss housing market. Quantitative Finance and Economics, 2021, 5(1): 67-93. doi: 10.3934/QFE.2021004
    [4] Richard J. Cebula, Robert Boylan . Uncertainty regarding the effectiveness of Federal Reserve monetary policies over time in the U.S.: an exploratory empirical assessment. Quantitative Finance and Economics, 2019, 3(2): 244-256. doi: 10.3934/QFE.2019.2.244
    [5] Andreas Tsalas, Platon Monokroussos . PIIGS in and out of sync: the changing face of financial business cycle synchronization in Europe. Quantitative Finance and Economics, 2018, 2(1): 261-278. doi: 10.3934/QFE.2018.1.261
    [6] Afees A. Salisu, Rangan Gupta, Siphesihle Ntyikwe, Riza Demirer . Gold and the global financial cycle. Quantitative Finance and Economics, 2023, 7(3): 475-490. doi: 10.3934/QFE.2023024
    [7] Jorge A. Chan-Lau . Systemic centrality and systemic communities in financial networks. Quantitative Finance and Economics, 2018, 2(2): 468-496. doi: 10.3934/QFE.2018.2.468
    [8] Oleg S. Sukharev . Structural analysis of income and risk dynamics in models of economic growth. Quantitative Finance and Economics, 2020, 4(1): 1-18. doi: 10.3934/QFE.2020001
    [9] Yue Liu, Yuhang Zheng, Benjamin M Drakeford . Reconstruction and dynamic dependence analysis of global economic policy uncertainty. Quantitative Finance and Economics, 2019, 3(3): 550-561. doi: 10.3934/QFE.2019.3.550
    [10] Frédéric Tronnier, Weihua Qiu . How do privacy concerns impact actual adoption of central bank digital currency? An investigation using the e-CNY in China. Quantitative Finance and Economics, 2024, 8(1): 126-152. doi: 10.3934/QFE.2024006
  • Neuroendocrine-immune homeostasis in health and disease is a tightly regulated bidirectional network that influences predisposition, onset and progression of age-associated disorders. The complexity of interactions among the nervous, endocrine and immune systems necessitates a complete review of all the likely mechanisms by which each individual system can alter neuroendocrine-immune homeostasis and influence the outcome in age and disease. Dysfunctions in this network with age or external/internal stimuli are implicated in the development of several disorders including autoimmunity and cancer. The existence of sympathetic noradrenergic innervations on lymphoid organs in synaptic association with immune cells that express receptors for endocrine mediators such as hormones, neural mediators such as neurotransmitters and immune effector molecules such as cytokines explains the complicated nature of the regulatory pathways that must always maintain homeostatic equilibrium within and among the nervous, endocrine and immune systems. The incidence, development and progression of cancer, affects each of the three systems by disrupting regulatory pathways and tipping the scales away from homeostasis to favour pathways that enable it to evade, override and thrive by using the network to its advantage. In this review, we have explained how the neuroendocrine-immune network is altered in female reproductive aging and cancer, and how these modulations contribute to incidence and progression of cancer and hence prove to be valuable targets from a therapeutic standpoint. Reproductive aging, stress-associated central pathways, sympathetic immunomodulation in the periphery, inflammatory and immunomodulatory changes in central, peripheral and tumor-microenvironment, and neuro-neoplastic associations are all likely candidates that influence the onset, incidence and progression of cancer.



    Overfishing occurs when fish are harvested at a rate faster than the resource can replenish itself. This practice has consequences that extend beyond the depletion of single-species fish populations, potentially leading to global food insecurity, ecological extinction, and other devastating effects[1,2,3,4]. Marine ecosystems and their associated livelihoods worldwide are threatened by overfishing. Nicholas et al. [5] have shown that overfishing is pushing over one-third of all sharks and rays towards global extinction. They suggest that marine life could face a future similar to that of land biodiversity, where human pressures have resulted in the loss of numerous species, possibly triggering a sixth mass extinction. According to IUCN Red List criteria [6], they estimate that one-quarter of 1,041 chondrichthyan fishes are threatened due to overfishing (both targeted and incidental). Therefore, it is urgent to establish the optimal harvesting strategy (OHS) for overfishing to prevent extinctions and promote population recovery. Consequently, investigating OHS has significant implications for marine ecosystems.

    Mathematical models are widely utilized to analyze the OHS of populations [7,8,9,10,11,12,13]. Clark [7] proposes several deterministic population systems with harvesting and establishes the OHS. Martin and Ruan [8] investigate the predator-prey models with delay and prey harvesting. However, nature is full of random phenomena, and various populations in the ecosystem experience different forms of random perturbations. May [9] indicates that environmental noise affects competition coefficient, environmental capacity, the growth rate and other parameters of population systems. Lande et al.[10] demonstrate that the extinction of numerous species caused by over-harvesting may be largely due to the ignorance of randomness. Therefore, it is crucial to investigate the OHS of population system in random environment. Li and Wang [11] establish a general stochastic logistic population model with white noises and explore the optimal harvesting policy. Wang et al.[12] propose a stochastic predator-prey model with time delays and shows how randomness influences the extinction and OHS. Therefore, exploring the OHS of stochastic marine population systems is meaningful.

    Lévy noise, another type of environmental perturbations, is considered below. During the process of species evolution, population growth is often affected by random disturbances in the environment, such as toxic pollutants, epidemics, earthquakes, floods and other factors [14,15,16,17]. For example, the Sandoz chemical accident in 1986 resulted in the death of over 600,000 fish in the Rhine [14], while the 2010 Gulf of Mexico oil spill caused a devastating impact on marine life in the Gulf of Mexico [15]. Bao et al. [16] propose that non-Gaussian Lévy noise is suitable for concluding these phenomena and revealed that Lévy noise can inhibit the explosive increase of population. Zhang et al. [17] also proposed to use Lévy noise to describe the random perturbations.

    A lot of work has been done to study the stochastic food chain population dynamics model so far. Our previous work has investigated the dynamics of a stochastic three species food chain model in [18], the dynamics of a four-species stochastic food chain model with delays in [19] and the dynamic behaviors of a stochastic n-species food chain model with Lévy noises and white noises in [20] as follows:

    {dx1(t)=x1(t)[r1a11x1(t)a12x2(t)]dt+σ1x1(t)dB1(t)+Zx1(t)γ1(u)˜N(dt,du),dxi(t)=xi(t)[riaiixi(t)+aii1xi1(t)aii+1xi+1(t)]dt+σixi(t)dBi(t)+Zxi(t)γi(u)˜N(dt,du),2in1,dxn(t)=xn(t)[rnannxn(t)+ann1xn1(t)]dt+σnxn(t)dBn(t)+Zxn(t)γn(u)˜N(dt,du). (1.1)

    By introducing a new research method, that is algebraic approach, the sufficient and necessary criteria for the stochastic extinction, persistence in mean and global stability are established in [20]. These conclusions directly generalize some research results on three and four species stochastic food chain dynamics models in [18,19]. However, due to the high dimensionality of model (1.1) and technical difficulties, the stability in distribution and optimal harvesting problems have not been discussed until now. In this paper, we consider the effects of harvesting and Lévy noises, then address these issues by proposing a stochastic n-species food chain model as follows:

    {dx1(t)=x1(t)[r1h1a11x1(t)a12x2(t)]dt+σ1x1(t)dB1(t)+Zx1(t)γ1(u)˜N(dt,du),dxi(t)=xi(t)[rihiaiixi(t)+aii1xi1(t)aii+1xi+1(t)]dt+σixi(t)dBi(t)+Zxi(t)γi(u)˜N(dt,du),2in1,dxn(t)=xn(t)[rnhiannxn(t)+ann1xn1(t)]dt+σnxn(t)dBn(t)+Zxn(t)γn(u)˜N(dt,du). (1.2)

    On the basis of the research results in [20], our primary objective is to establish criteria for the stability in distribution of model (1.2). Additionally, we aim to establish criteria for the optimal harvesting strategy in the sense of sustainable yield. Lastly, we will verify the theoretical results through numerical examples and propose some open questions and propositions.

    This paper is organized as follows. In Section 2, we provide the basic assumption, and further introduce several important lemmas that will be used to prove the major results. In Section 3, we state and prove the stability in distribution of model (1.2). In Section 4, we outline the non-existence and existence criteria for OHS and MESY. Finally, in Section 5, we illustrate our major results through numerical examples.

    Denote by (Ω,{Ft}t0,P) the complete probability space, and its filtration {Ft}t0 satisfies the usual conditions. In this paper, we assume that model (1.2) is defined on the probability space (Ω,{Ft}t0,P). In addition, for an integrable function f(t) defined for t[0,+), we define the mean value of f(t) on interval [0,t] for any t>0 by f(t)=1tt0f(s)ds.

    In models (1.1) and (1.2), parameter r1>0 is the intrinsic growth rate of species x1, ri0 represents the death rate of species xi for i=2,3,,n, hi0 represents the harvesting rate of human for the species xi for i=1,2,,n, xi(t) is the left limit of xi(t) at time t, aii>0(i=1,2,,n) is the density dependent coefficient of species xi, aii+10(i=2,3,,n1) is the capture rate of which species xi+1 preys on species xi, aii10(i=2,3,,n) stands for efficiency of food conversion from species xi1 to species xi. Bi(t)(i=1,2,,n) are independent standard Brownian motion, and σ2i>0 is the intensity of Bi(t). Lévy noises ˜N(dt,du)=N(dt,du)λ(du)dt, where N(dt,du) is a poisson counting measure with characteristic measure λ on a Borel-measurable subset Z of (0,) satisfying λ(Z)<+. Functions γi(u):ZR(i=1,2,,n) represent the effects of random jumps for species xi that are assumed to be continuous on Z. In this paper we further assume that Lévy noises ˜N(dt,du) and Brownian motion Bi(t)(i=1,2,,n) are also independent.

    For any solution (x1(t),,xn(t)) of model (1.2), the initial value is given as follows.

    xi(0)=xi0,i=1,2,,n, (2.1)

    where xi0(i=1,2,,n) are positive constants.

    Denote bi=ri+z[ln(1+γi(u))γi(u)]λ(du)σ2i2 and ci=bihi for i=1,2,,n, and αk=(c1,c2,,ck)T for k=1,2,,n. Furthermore, we denote

    Ak=[a11a120000a21a22a23000000ak1k2ak1k1ak1k0000akk1akk].

    Particularly, we have

    A1=[a11],A2=[a11a12a21a22].

    Denote by Hk the determinant of Ak. Let A(i)k be the matrix gained from matrix Ak by changing its i-th column to αk, and D(i)k is the determinant of A(i)k. Furthermore, for any square matrix P we denote by P(i,j) the algebraic complement corresponding to the element of i-th row and j-th column of P.

    For the Lévy noises in models (1.1) and (1.2), we always assume that the following condition is satisfied.

    (H) For i=1,2,,n and uZ, 1+γi(u)>0 holds, and a constant z>0 exists such that

    Z[ln(1+γi(u))]2λ(du)<z.

    Using the same method as in [20], the following conclusions can be established for model (1.2).

    Lemma 1. Hk>0 for every k=1,2,,n.

    Lemma 2. For any initial values (x10,x20,,xn0)Rn+, model (1.2) possesses a globally unique positive solution x(t)=(x1(t),,xn(t))Rn+a.s. for all t0 satisfying the initial condition (2.1). Furthermore, for any constant q>0, there are constants Ci(q)>0(i=1,2,,n) such that

    lim suptE[xqi(t)]Ci(q),i=1,2,,n.

    Similar to [20], we define

    N1=a12a11A(2)k(3,2)Hk(3,k),Ni=aii1aiiNi1+aii+1aiiA(i+1)k(i+2,i+1)Hk(i+2,k),i=1,2,,k2,Nk1=ak1k2ak1k1Nk2.

    Lemma 3. For any positive solution (x1(t),,xn(t)) of model (1.2), assume that D(n)n>0 and (1+ann1annNn1)>0 if n3, then limtxi(t)=D(i)nHn a.s., i=1,2,,n.

    A simple calculation we can obtain that for any integers k,i,j{1,2,,n} with i,jk

    A(i)k(j,i)=Ak(j,i).

    Therefore, we further have

    N1=a12a11Ak(3,2)Hk(3,k),Ni=aii1aiiNi1+aii+1aiiAk(i+2,i+1)Hk(i+2,k),i=1,2,,k2,Nk1=ak1k2ak1k1Nk2. (2.2)

    Theorem 1. Let (x1(t;ψ),x2(t;ψ),,xn(t;ψ)) and (z1(t;ψ),z2(t;ψ),,zn(t;ψ)) be two solutions of model (1.2) with initial values ψ,ψRn+. Assume that there are positive constants wi(i=1,2,,n) such that

    w1a11w2a21>0,wiaiiwi1ai1iwi+1ai+1i>0(i=2,3,,n1),wnannwn1an1n>0.

    Then we have

    limtE(ni=1|xi(t,ψ)zi(t,ψ)|2)12=0.

    Proof. We only need to show

    limtE|xi(t;ψ)zi(t;ψ)|=0,i=1,2,,n. (3.1)

    Define the functions as follows

    Vi(xi)=|lnxi(t;ψ)lnzi(t;ψ)|,i=1,2,,n.

    Applying Itô formula, then

    LVi(xi)aii|xi(t;ψ)zi(t;ψ)|+aii1|xi1(t;ψ)zi1(t;ψ)|+aii+1|xi+1(t;ψ)zi+1(t;ψ)|,i=1,2,,n. (3.2)

    where a10=ann+1=0 are stupulated. Define the following function

    V(t)=ni=1wiVi(xi). (3.3)

    From (3.1) we obtain

    LV(t)=ni=1wiLVi(xi)ni=1(wiaiiwi1ai1iwi+1ai+1i)|xi(t;ψ)zi(t;ψ)|,

    where a01=an+1n=0 and ω0=ωn+1=0 are stipulated. Therefore,

    E[V(t)]E[V(0)]ni=1(wiaiiwi1ai1iwi+1ai+1i)t0E[|xi(s;ψ)zi(s;ψ)]|ds.

    which implies

    0E[|xi(s;ψ)zi(s;ψ)|]ds<+,i=1,2,,n. (3.4)

    Define the functions

    Fi(t)=E[|xi(t;ψ)zi(t;ψ)|],i=1,2,,n.

    Then, for any t1,t2[0,+) and each i=1,2,,n,

    |Fi(t2)Fi(t1)|=|E[|xi(t2;ψ)zi(t2;ψ)||xi(t1;ψ)zi(t1;ψ)|]|E[|xi(t2;ψ)xi(t1;ψ)|]+E[|zi(t2;ψ)zi(t1;ψ)|]. (3.5)

    Applying Itô formula to model (1.2), then

    xi(t2;ϕ)xi(t1;ϕ)=t2t1xi(s;ϕ)[rihi+aii1xi1(s;ϕ)aiixi(s)aii+1xi+1(s;ϕ)]ds+t2t1σixi(s;ϕ)dBi(s)+t2t1Zxi(s)γi(u)˜N(ds,du),i=1,2,...,n. (3.6)

    For any t2>t1 and q>1, from the first equation of (3.6) and Hölder's inequality, then

    (E[|x1(t2;ψ)x1(t1;ψ)|])qE[(t2t1x1(s;ψ)|r1h1a11x1(s;ψ)a12x2(s;ψ)|ds+|t2t1σ1x1(s;ψ)dB1(s)|)q]+|t2t1Zx1(s)γ1(u)˜N(ds,du)|3qE[(t2t1x1(s;ψ)|r1h1a11x1(s;ψ)a12x2(s;ψ)|ds)q]+3qE[|t2t1σ1x1(s;ψ)dB1(s)|q]+3qE[|t2t1Zxi(s)γi(u)˜N(ds,du)|q]. (3.7)

    Similarly,

    E[(t2t1x1(s;ψ)|r1h1a11x1(s;ψ)a12x2(s;ψ)|ds)q](t2t1)q1E[t2t1(|r1h1|x1(s;ψ)+a11x21(s;ψ)+a12x1(s;ψ)x2(s;ψ))qds]3q(t2t1)q1|r1h1|qt2t1E[xq1(s;ψ)]ds+3qaq11(t2t1)q1t2t1E[x2q1(s;ψ)]ds+3q(t2t1)q1E[t2t1(a12x1(s;ψ)x2(s;ψ))qds]. (3.8)

    and

    E[t2t1(a12x1(s;ψ)x2(s;ψ))qds]E[t2t1(12a12x21(s;ψ)+12a12x22(s;ψ))qds]aq12t2t1E[x2q1(s;ψ)]ds+aq12t2t1E[x2q2(s;ψ)]ds. (3.9)

    In view of Theorem 7.1 in [21] on the Burkholder-Davis-Gundy inequality, for 1<q2 and any t2>t1, then

    E[|t2t1σ1x1(s;ψ)dB1(s)|q]DqE[t2t1|σ1x1(s;ψ)|2ds]q/2Dqσq1(t2t1)q22t2t1E[xq1(s;ψ)]ds. (3.10)

    Using the Kunita first inequality in [21], there exists a constant Kq>0 and from assumption (H) we can obtain

    E[|t2t1Zx1(s;ψ)γ1(u)˜N(ds,du)|q]KqE[t2t1Z|x1(s)γ1(u)|2λ(du)ds]q/2+E[t2t1Z|x1(s)γ1(u)|qλ(du)ds]KqLq/2(t2t1)q22t2t1E[xq1(s;ψ)]ds+KqLq/2t2t1E[xq1(s;ψ)]ds. (3.11)

    From Lemma 2, there exists Ci(q)>0 for i=1,2,,n such that suptγE[xqi(t)]Ci(q). Therefore, from (3.7)–(3.10) there is a δ>0 satisfies that for 1<q2 and any t10,t20 with |t2t1|δ, such that

    (E[|x1(t2;ψ)x1(t1;ψ)|])q3q[Dqσq1(t2t1)q2C1(q)]+(t2t1)q23q[KqLq/2C1(q)+KqLq/2(t2t1)1q/2C1(q)]+3q[3q(t2t1)q|r1h1|qC1(q)+3qaq11(t2t1)qC1(2q)]+32q(t2t1)qaq12[C1(2q)+C2(2q)]M1|t2t1|q2,

    where

    M1=3qDqσq1C1(q)+3qKqLq/2[1+δ2q2]C1(q)+[81δ]q2[|r1h1|qC1(q)+aq11C1(2q)]+[81δ]q2aq12[C1(2q)+C2(2q)].

    Similarly, we also obtain

    (E[|z1(t2;ψ)z1(t1;ψ)|])qM1|t2t1|q2.

    for any t10,t20 with |t2t1|δ and 1<q2. Thus, from (3.5), we obtain

    |F1(t2)F1(t1)|E[|x1(t2;ψ)x1(t1;ψ)|]+E[|z1(t2;ψ)z1(t1;ψ)|]2(M1)1q|t2t1|. (3.12)

    Using similar argument, for Fi(t)(i=2,3,,n), we also can obtain that there is a δ>0 for any t10,t20 with |t2t1|δ and 1<q2

    |Fi(t2)Fi(t1)|2(Mi)1q|t2t1|,i=2,3,,n, (3.13)

    where

    Mi=3qDqσqiCi(q)+3qKqLq/2[1+δ2q2]Ci(q)+[144δ]q2[|ri+hi|qCi(q)+aqiiCi(2q)]+[144δ]q2aqii+1[Ci(2q)+Ci+1(2q)]+[144δ]q2aqii1[Ci1(2q)+Ci+1(2q)],i=2,3,,n.

    From (3.12) and (3.13), we obtain that Fi(t),i=1,2,,n for t(0,) are uniformly continuous. Therefore, from (3.4) and Barbalat lemma in [22] we finally obtain that (3.1) holds. This completes the proof.

    Let P(Rn+) be the space of all probability measures on C(Rn+). For Q1,Q2P(Rn+), we define

    dLB(Q1,Q2)=supfLB|Rn+f(y)Q1(dy)Rn+f(y)Q2(dy)|, (3.14)

    where

    LB={f:Rn+R:|f(y1)f(y2)|y1y2,|f()|1}. (3.15)

    Denote by p(t,ϕ,dx) the transition probability of process x(t)=(x1(t),x2(t),,xn(t)). We have the following results.

    Theorem 2. Assume that there exists constants wi>0(i=1,2,,n) such that

    w1a11w2a21>0,wiaiiwi1ai1iwi+1ai+1i>0(i=2,3,,n1),wnannwn1an1n>0.

    Then model (1.2) is asymptotically stable in distribution, that is, there is a probability measure v() satisfies that for any initial function ψRn+, the transition probability p(t,ψ,) of solution (x1(t,ψ),x2(t,ψ),,xn(t,ψ)) such that

    limtdLB(p(t,ψ,),v())=0.

    Proof. For any initial data ψRn+, the family probability p(t,ψ,) is tight which obtained from Theorem 1 and Chebyshev's inequality. For any fLB and t,s>0, we compute

    Ef(y(t+s;ψ))p(t+s,ψ,dy)Ef(y(t;ψ))p(t,ψ,dy)=E[E(f(y(t+s;ψ))Fs)]E[f(y(t;ψ))]=Rn+E[f(y(t;ϕ))]p(s,ψ,dϕ)E[f(y(t;ψ))]∣≤Rn+Ef(y(t;ϕ))Ef(y(t;ψ))p(s,ψ,dϕ).

    It is clear that there exists a constant T>0 from (3.1), such that for all tT,

    supfLBEf(y(t;ϕ))Ef(y(t;ψ))∣≤ε.

    Consequently

    Ef(y(t+s;ψ))Ef(y(t;ψ))∣≤ε.

    Since f is arbitrary, we gain

    supfLBEf(y(t+s;ψ))Ef(y(t;ψ))∣≤ε.

    That is,

    dLB(p(t+s,ψ,),p(t,ψ,))ε.

    Therefore {p(t,ψ,):t0} is Cauchy in the space P(Rn+). Hence, there is a unique v()P(Rn+) such that

    limtdLB(p(t,ψ0,),v())=0.

    where ψ0=(c10,c20,...,cn0)TRn+, and c10,,cn0 are positive constants. It then follows from (3.1) that

    limtdLB(p(t,ψ,),p(t,ψ0,)=0.

    Hence,

    limtdLB(p(t,ψ,),v()limtdLB(p(t,ψ,),p(t,ψ0,))+limtdLB(p(t,ψ0,),v())=0.

    This completes the proof.

    Since Hn>0 in Lemma 1, the inverse matrix A1n exists. Let B=(b1,b2,,bn)T and H=(h1,h2,,hn)T. Moreover, let E be the unit matrix, and H=(An(A1n)T+E)1B(h1,h2,,hn)T.

    Theorem 3. Assume that the following conditions hold

    (1) (1+ann1annNn1)>0 if n3;

    (2) there exists constants wi>0(i=1,2,,n) such that

    w1a11w2a21>0,wiaiiwi1ai1iwi+1ai+1i>0(i=2,3,,n1),wnannwn1an1n>0.

    Then the following conclusions hold.

    (A1) If D(n)n|hi=hi>0, A1n+(A1n)T is positive semi-definite and hi0 (i=1,2,,n), then model (1.2) has the OHS H=H, and

    MESYS(H)=(H)TA1n(BH). (4.1)

    (A2) If any of the following conditions stands, then the OHS for model (1.2) does not exist.

    (B1) D(n)n|hi=hi,i=1,2,,n0;

    (B2) There is a hi with hi<0;

    (B3) A1n+(A1n)T is not positive semi-definite.

    Proof. Let Y={H=(h1,h2,,hn)TRn:D(n)n>0,hi0,i=1,2,,n}, which means that for any HY, the conclusion of Lemma 3 stands.

    First, we prove the conclusion (A1). Since HY, the set Y is not empty. A unique probability measure v() is gained from Theorem 2. Then, v() is also strong mixing by Corollary 3.4.3 [23]. From Theorem 3.2.6[23], we gain that the measure v() is ergodic. For any initial value ψRn+, model (1.2) possess a positive gloabl solution x(t)=(x1(t),x2(t),,xn(t)). It yields by Theorem 3.3.1 [23] that

    limt1tt0HTx(s)ds=Rn+HTxv(dx), (4.2)

    where H=(h1,h2,,hn)TY. Let ϱ(z) be the stationary probability density of model (1.2), then we have

    S(H)=limtE[ni=1hixi(t)]=limtE[HTx(t)]=Rn+HTxϱ(x)dx. (4.3)

    In view of the invariant measure is sole, there also exists a one-to-one correspondence among ϱ(z) and its corresponding invariant measure. Hence, we have

    Rn+HTxϱ(x)dx=Rn+HTxv(dx). (4.4)

    Combining (4.2)–(4.4) with the conclusion of Lemma 3, then

    S(H)=limt+1tt0HTx(s)ds=h1limt+1tt0x1(s)ds+h2limt+1tt0x2(s)ds++hnlimt+1tt0xn(s)ds=h1D(1)nHn+h2D(2)nHn++hnD(n)nHn.

    Moreover, S(H)=HT(An)1(BH) is derived by careful calculation. Computing the gradient of S(H), then

    S(H)H=HTH(An)1(BH)+(BH)TH((An)1)TH.

    Since HTH=E, then

    S(H)H=(An)1(BH)((An)1)TH=(An)1B((An)1+((An)1)T)H.

    By solving S(H)H=0, the following critical value is gained

    H=((An)1+((An)1)T)1(An)1B.

    That is,

    H=[(An)1((An)((An)1)T+E)]1(An)1B=((An)((An)1)T+E)1B=H.

    Calculating the Hessian matrix of S(H), we obtain

    H(S(H)H)=((An)1+((An))T)HH=((An)1+((An)1)T). (4.5)

    Since (An)1+((An)1)T is positive semi-definit, from the existence principle of extremum value of multi-variable function we obtain that S(H) has a global maximum value at H=H. Obviously, H is also sole. Therefore, if HY, that is hi0(i=1,2,,n) and D(n)n|hi=hi,i=1,2,,n>0, then we finally obtain that H is an OHS, and MESY shown in (20).

    Next, we prove the conclusion (A2). We first assume that (B1) or (B2) stands. Suppose that ˜Γ=(γ1,γ2,,γn) is the OHS for model (1.2), thus ΓY, that is

    D(n)n|hi=γi,i=1,2,,n>0,γi0,i=1,2,,n. (4.6)

    On the other hand, if ΓY is the OHS, then Γ is a unique solution of equation S(H)H=0. Therefore, we have (h1,h2,,hn)=(γ1,γ2,,γn). Thus, condition (4.6) becomes into

    D(n)n|hi=hi,i=1,2,,n>0,hi0,i=1,2,,n.

    However, this is impossible.

    Finally, consider (B3). It can be assumed that (B1) and (B2) fail to stand in this case. Therefore, hi0(i=1,2,,n) and D(n)n|hi=hi,i=1,2,,n>0. Thus, Y is not empty, i.e., (4.2)(4.4) hold. Denote (An)1+((An)1)T=(hij)n×n. Then, by calculating we have

    h11=2(a22a33ann++a22a34ann1+a23a32ann)Hn

    Obviously, h11>0, which means that (An)1+((An)1)T is not negative semi-definite. It can be further derived from the conditions in (B3) that (An)1+((An)1)T is indefinite. Hence, there is not the OHS if B3 holds. This completes the proof.

    Remark 1. In Theorem 3 we see that the conditions (1) and (2) are required. From the following argumentations we will find that when n=3 and n=4 condition (2) can bring out condition (1). Therefore, we propose the following proposition. However, when n>4 whether condition (2) can bring out condition (1) still is an open problem. Thus, the following conjecture can be proposed.

    Proposition 1. When n=3 and n=4, if condition (2) holds then condition (1) also holds.

    Proof. Let k=3, then condition (2) becomes to

    w1a11w2a21>0,w2a22w1a12w3a32>0w3a33w2a23>0. (4.7)

    From (2.2), by calculating we have

    N1=a12a23a11a22+a12a21,N2=a12a21a23a22(a11a22+a12a21),

    and

    1+a32a33N2=a22a33(a11a22+a12a21)a12a21a23a32a22a33(a11a22+a12a21).

    From (4.7) we derive

    a221w2(w1a12)+w3a32,a33w2a23w3.

    Therefore, we further have

    a22a33(a11a22+a12a21)a12a21a23a32>[1w2(w1a12+w3a32)1w3w2a23(a11a22+a12a21)]a12a21a23a32=(w1a12w2w3+a32w2)w2a23(a11a22+a12a21)a12a21a23a32=(w1a12a23w3+a23a32)(a11a22+a12a21)a12a21a23a32=w1a12a23w3(a11a22+a12a21)+a11a22a23a32>0.

    This shows that 1+a32a33N2>0.

    Let k=4, then condition (2) becomes to

    w1a11w2a21>0,w2a22w1a12w3a32>0,w3a33w2a23w4a43>0,w4a44w3a34>0. (4.8)

    From (2.2), by calculating, we have

    N1=a12a23a44a43H2,N2=(a12a21a23a44H3+a23a34a43H22)a22a43H2H3,N3=a32(a12a21a23a44H3+a23a34a43H22)a33a22a43H2H3,

    and

    1+a43a44N3=1(a12a21a23a32a44H3+a23a32a34a43H22)a22a33a44H2H3=a22a33a44H2H3a12a21a23a32a44H3a23a32a34a43H22a22a33a44H2H3.

    From (4.8) we obtain

    a11>w2w1a21,aii>1wi(wi1ai1i+wi+1ai+1i),i=2,3,a44>w3w4a34.

    Therefore,

    (a22a33H2a12a21a23a32)a44H3>(1w2[w1a12+w3a32]1w3[w2a23+w4a43][a11a22+a12a21]a12a21a23a32)a44H3((1w2w1a121w3[w2a23+w4a43]+w4w2a32a43)(a11a22+a12a21))a44H3w4w2a32a43(a11a22+a12a21)w3w4a34H3.

    Since

    H3>(a11a22+a12a21)a33>(a11a22+a12a21)w2w3a23,

    we further obtain

    (a22a33H2a12a21a23a32)a44H3>w4w2a32a43(a11a22+a12a21)w3w4a34(a11a22+a12a21)w2w3a23=a23a32a34a43H22.

    This shows that 1+a43a44N3>0.

    Conjecture 1. When n>4, if condition (2) holds then condition (1) also holds.

    To support our analysis results, we will provide the numerical examples for model (1.2). The numerical simulations can be performed qualitatively, and parameters are selected in an epidemiologically feasible way.

    Example 1. In model (1.2) we take n=4, r1=1.5, r2=0.6, r3=0.08, r4=0.01, γ1=0.1, γ2=0.15, γ3=0.15, γ4=0.1, a11=1.6, a12=0.2, a22=2.2, a21=2.5, a23=0.1, a32=2.5, a33=2, a34=0.3, a43=1.3, a44=2, σ1=0.1, σ2=0.2, σ3=0.1 and σ4=0.1

    Choose w1=2.5, w2=1.3, w3=0.8 and w4=0.5, by calculating we have w1a11w2a21=0.7500>0, w2a22w1a12w3a32=0.3600>0, w3a33w2a23w4a43=0.8200>0 and m4a44m3a34=0.7600>0. Proposition 1 shows that 1+a43a44N3>0. Thus, all four species in model (1.2) are persistent in mean which is shown in Figure 1 below. Furthermore, h1=0.3250, h2=0.3914, h3=0.3264, h4=0.1281 and D(4)4|hi=hi,i=1,2,3,4=0.5201>0 are obtained by calculating, all leading principal minors of A4+(A14)T are positive, which shows that the A4+(A14)T is positive semi-definite. Thus, the condition of conclusion (A1) is satisfied, then the OHS: H=(0.32500.39140.32640.1281)T and MESY=0.4321 are gained, as Figure 1 shows below.

    Figure 1.  The sample path for the solution and MESY illustrate that species xi(t)(i=1,2,3,4) is persistent in the mean and MESY exists. The brown line represent the solution of the corresponding undisturbed system and the blue lines represent the solution of model (1.2).

    Example 2. In model (1.2) we take n=4, r1=1.5, r2=0.5, r3=0.03, r4=0.01; γ1=0.15, γ2=0.2, γ3=0.1 and γ4=0.05. The rest parameters in model (1.2) are shown in the following three cases.

    Case 2.1. a11=1.6, a12=0.2, a22=2, a21=2.5, a23=1, a32=2.5, a33=2.1, a34=0.2, a43=0.1, a44=2, σ1=0.1, σ2=0.2, σ3=0.2 and σ4=0.1.

    Case 2.2. a11=1.8, a12=0.2, a22=2, a21=1.5, a23=0.2, a32=1.5, a33=2.1, a34=0.8, a43=1.1, a44=2.5, σ1=0.2, σ2=0.2, σ3=0.3 and σ4=0.1.

    Case 2.3. a11=0.8, a12=0.2, a22=2, a21=1, a23=0.15, a32=1.5, a33=2, a34=0.1, a43=1, a44=0.08, σ1=0.2, σ2=0.3, σ3=0.3 and σ4=0.1.

    For Case 2.1, choose w1=2.5, w2=1.3, w3=0.8 and w4=1.4, then we have w1a11w2a21=0.75>0, w2a22w1a12w3a32=0.10>0, w3a33w2a23w4a43=0.24>0 ºÍ m4a44m3a34=2.64>0. Furthermore, h1=0.3621, h2=0.4773, h3=0.4665, h4=0.0051 are gained by calculating. Meanwhile, D(4)4|hi=hi,i=1,2,3,4=0.1475<0. Thus the condition (B1) of (A2) is satisfied. Therefore, the OHS do not exist. The numerical simulations are given in Figure 2.

    Figure 2.  The sample path for the solution shows that species xi(t)(i=1,2,3) is persistent in the mean and x4 goes to extinction.

    For Case 2.2, choose w1=2.2, w2=1.1, w3=1.1 and w4=1.4, then we have w1a11w2a21=2.31>0, w2a22w1a12w3a32=0.11>0, w3a33w2a23w4a43=0.55>0 ºÍ m4a44m3a34=2.62>0. Furthermore, h1=0.9445>0, h2=0.2174>0, h3=0.0039>0 and h4=0.0124<0 are obtained by calculating. Thus the condition (B2) of conclusion (A2) is satisfied. Therefore, the OHS do not exist. The numerical simulations are given in Figure 3.

    Figure 3.  The sample path for the solution shows that species xi(t)(i=1,2,3) is persistent in the mean and x4 goes to extinction.

    For Case 2.3, choose w1=2.8, w2=2, w3=2 and w4=2.8, then we have w1a11w2a21=0.24>0, w2a22w1a12w3a32=0.44>0, w3a33w2a23w4a43=0.90>0 ºÍ m4a44m3a34=0.024>0. Furthermore, by calculating we obtain that the fourth leading principle minor of A4+(A14)T is equal to 6.2127<0, which means that A4+(A14)T is negative semi-definite. Thus the condition (B3) is satisfied. Therefore, the optimal harvesting strategy do not exist. The numerical simulations are given in Figure 4.

    Figure 4.  The sample path for the solution shows that species xi(t)(i=1,2,3) is persistent in the mean and x4 goes to extinction.

    In this paper, based on the effect of harvesting and Lévy noises, a stochastic marine n-species system is investigated. On the basis of the research results in [23], we first establish the criterion for the stability in distribution of model (1.2). Then, the criteria for existence and nonexistence of OHS and the corresponding MESY are derived. This shows that the environmental noises affect the OHS and MESY.

    Compared with the existing results, our first contribution is to investigate the stochastic stability and optimal harvesting problems for a stochastic marine n-species food chain model with Lévy noises and white noises. Second, the criteria on the stability in distribution and optimal harvesting strategy for stochastic n-species food chain model are established for the first time. Third, the noises intensity can easily affect the dynamics and MESY of marine populations, and further lead to the imbalances of marine ecology. Finally, we find that for better manage and protect marine resources, the establishment of an optimal harvesting strategy should fully consider the impact of noise intensity.

    There are still some remained problems that need to be followed up. For example, in Conjecture 1, we assume if w1a11w2a21>0wiaiiwi1ai1iwi+1ai+1i>0(i=23n1)wnannwn1an1n>0, then 1+ann1annNn1>0, how to prove is an open problem. Second, marine population are easily affected by climate change, consider marine population model with regime switching is necessary. Finally, more complex and realistic stochastic system with nonlinear functional response, delays and Allee effect need to be investigated. These issues may be investigated in the future.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This work was supported by the National Natural Science Foundation of China (Grant No. 12061079), Foundation of Fujian Educational Committee (Grant No. JAT220189), Startup Foundation of Jimei University(Grant No.ZQ2022025).

    The authors declare there is no conflicts of interest.


    Acknowledgments



    Supported by the Department of Science and Technology, Government of India, New Delhi under the Inspire Faculty Award Scheme of AORC (IFA15/LSBM-154).

    Conflict of interest



    The authors declare no conflict of interest.

    [1] Ader R, Felten DL, Cohen N (2001)  Psychoneuroimmunology New York: Academic Press.
    [2] Seifert P, Spitznas M (2001) Tumours may be innervated. Virchows Arch 438: 228-231. doi: 10.1007/s004280000306
    [3] Seifert P, Benedic M, Effert P (2002) Nerve fibers in tumors of the human urinary bladder. Virchows Arch 440: 291-297. doi: 10.1007/s004280100496
    [4] Lu SH, Zhou Y, Que HP, et al. (2003) Peptidergic innervation of human esophageal and cardiac carcinoma. World J Gastroenterol 9: 399-403. doi: 10.3748/wjg.v9.i3.399
    [5] Liang YJ, Zhou P, Wongba W, et al. (2010) Pulmonary innervation, inflammation and carcinogenesis. Sheng Li Xue Bao 62: 191-195.
    [6] Priyanka HP, ThyagaRajan S (2013) Selective modulation of lymphoproliferation and cytokine production via intracellular signaling targets by α1- and α2-adrenoceptors and estrogen in splenocytes. Int Immunopharmacol 17: 774-784. doi: 10.1016/j.intimp.2013.08.020
    [7] Meites J, Quadri SK (1987) Neuroendocrine theories of aging. The Encyclopedia of Aging New York: Springer, 474-478.
    [8] ThyagaRajan S, MohanKumar PS, Quadri SK (1995) Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: effects of aging. Brain Res 689: 122-128. doi: 10.1016/0006-8993(95)00551-Z
    [9] ThyagaRajan S, Priyanka HP (2012) Bidirectional communication between the neuroendocrine system and the immune system: relevance to health and diseases. Ann Neurosci 19: 40-46.
    [10] Mravec B, Gidron Y, Hulin I (2008) Neurobiology of cancer: interactions between nervous, endocrine and immune systems as a base for monitoring and modulating the tumorigenesis by the brain. Semin Cancer Biol 18: 150-163. doi: 10.1016/j.semcancer.2007.12.002
    [11] Mukhtar RA, Nseyo O, Campbell MJ, et al. (2011) Tumor-associated mac-rophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11: 91-100. doi: 10.1586/erm.10.97
    [12] Müller A, Homey B, Soto H, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56. doi: 10.1038/35065016
    [13] Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322. doi: 10.1016/j.ccr.2012.02.022
    [14] Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi: 10.1016/j.cell.2011.02.013
    [15] Cole SW, Nagaraja AS, Lutgendorf SK, et al. (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer 15: 563-572. doi: 10.1038/nrc3978
    [16] Segerstrom SC, Miller GE (2004) Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull 130: 601-630. doi: 10.1037/0033-2909.130.4.601
    [17] Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51: 27-41. doi: 10.1016/j.immuni.2019.06.025
    [18] Yang H, Xia L, Chen J, et al. (2019) Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med 25: 1428-1441. doi: 10.1038/s41591-019-0566-4
    [19] Curtin NM, Boyle NT, Mills KH, et al. (2009) Psychological stress suppresses innate IFN-gamma production via glucocorticoid receptor activation: reversal by the anxiolytic chlordiazepoxide. Brain Behav Immun 23: 535-547. doi: 10.1016/j.bbi.2009.02.003
    [20] Key TJ (1995) Hormones and cancer in humans. Mutat Res 333: 59-67. doi: 10.1016/0027-5107(95)00132-8
    [21] Mravec B, Tibensky M, Horvathova L (2020) Stress and cancer. Part I: Mechanisms mediating the effect of stressors on cancer. J Neuroimmunol 346: 577311. doi: 10.1016/j.jneuroim.2020.577311
    [22] Yin W, Gore AC (2006) Neuroendocrine control of reproductive aging: roles of GnRH neurons. Reproduction 131: 403-414. doi: 10.1530/rep.1.00617
    [23] Reed BG, Carr BR (2000) The Normal Menstrual Cycle and the Control of Ovulation. Endotext South Dartmouth (MA): MDText.com, Inc.
    [24] Del Río JP, Alliende MI, Molina N, et al. (2018) Steroid Hormones and Their Action in Women's Brains: The Importance of Hormonal Balance. Front Public Health 6: 141. doi: 10.3389/fpubh.2018.00141
    [25] Djahanbakhch O, Ezzati M, Zosmer A (2007) Reproductive ageing in women. J Pathol 211: 219-231. doi: 10.1002/path.2108
    [26] Braunwald E, Isselbacher KJ, Petersdorf RG, et al. (1987)  Harrison's Principles of Internal Medicine New York: McGraw-Hill, 1818-1837.
    [27] Priyanka HP, Nair RS (2020) Neuroimmunomodulation by estrogen in health and disease. AIMS Neurosci 7: 401-417. doi: 10.3934/Neuroscience.2020025
    [28] Sherman BM, West JH, Korenman SG (1976) The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 42: 629-636. doi: 10.1210/jcem-42-4-629
    [29] Hall JE, Gill S (2001) Neuroendocrine aspects of aging of aging in women. Endocrinol Metab Clin North Am 30: 631-646. doi: 10.1016/S0889-8529(05)70205-X
    [30] Lang TJ (2004) Estrogen as an immunomodulator. Clin Immunol 113: 224-230. doi: 10.1016/j.clim.2004.05.011
    [31] Salem ML (2004) Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy 3: 97-104. doi: 10.2174/1568010043483944
    [32] Wise PM, Scarbrough K, Lloyd J, et al. (1994) Neuroendocrine concomitants of reproductive aging. Exp Gerontol 29: 275-283. doi: 10.1016/0531-5565(94)90007-8
    [33] Chakrabarti M, Haque A, Banik NL, et al. (2014) Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res Bull 109: 22. doi: 10.1016/j.brainresbull.2014.09.004
    [34] ThyagaRajan S, Madden KS, Teruya B, et al. (2011) Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats. J Neuroimmunol 233: 54-64. doi: 10.1016/j.jneuroim.2010.11.012
    [35] Teilmann SC, Clement CA, Thorup J, et al. (2006) Expression and localization of the progesterone receptor in mouse and human reproductive organs. J Endocrinol 191: 525-535. doi: 10.1677/joe.1.06565
    [36] Butts CL, Shukair SA, Duncan KM, et al. (2007) Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion. Int Immunol 19: 287-296. doi: 10.1093/intimm/dxl145
    [37] Jones LA, Kreem S, Shweash M, et al. (2010) Differential modulation of TLR3- and TLR4-mediated dendritic cell maturation and function by progesterone. J Immunol 185: 4525-4534. doi: 10.4049/jimmunol.0901155
    [38] Menzies FM, Henriquez FL, Alexander J, et al. (2011) Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology 134: 281-291. doi: 10.1111/j.1365-2567.2011.03488.x
    [39] Hardy DB, Janowski BA, Corey DR, et al. (2006) Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-κB activation of cyclooxygenase 2 expression. Mol Endocrinol 20: 2724-2733. doi: 10.1210/me.2006-0112
    [40] Arruvito L, Giulianelli S, Flores AC, et al. (2008) NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J Immunol 180: 5746-5753. doi: 10.4049/jimmunol.180.8.5746
    [41] Piccinni MP, Giudizi MG, Biagiotti R, et al. (1995) Progesterone favors the development of human T helper cells producing TH2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established TH1 cell clones. J Immunol 155: 128-133.
    [42] Özdemir BC, Dotto GP (2019) Sex hormones an anticancer immunity. Clin Cancer Res 25: 4603-4610. doi: 10.1158/1078-0432.CCR-19-0137
    [43] Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427. doi: 10.1016/S0140-6736(03)14596-5
    [44] Grady D, Gebretsadik T, Kerlikowske K, et al. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313. doi: 10.1016/0029-7844(94)00383-O
    [45] Lacey JV, Mink PJ, Lubin JH, et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288: 334-341. doi: 10.1001/jama.288.3.334
    [46] Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies results from the E3N cohort study. Breast Cancer Res Treat 107: 103-111. doi: 10.1007/s10549-007-9523-x
    [47] Anderson GL, Limacher M, Assaf AR, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712. doi: 10.1001/jama.291.14.1701
    [48] Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205-212. doi: 10.1038/bjc.1988.44
    [49] Cook MB, Dawsey SM, Freedman ND, et al. (2009) Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 18: 1174-1182. doi: 10.1158/1055-9965.EPI-08-1118
    [50] Cook MB, McGlynn KA, Devesa SS, et al. (2011) Sex disparities in cancer mortality and survival. Cancer Epidemiol. Biomarkers Prev 20: 1629-1637. doi: 10.1158/1055-9965.EPI-11-0246
    [51] Lista P, Straface E, Brunelleschi S, et al. (2011) On the role of autophagy in human diseases: a gender perspective. J Cell Mol Med 15: 1443-1457. doi: 10.1111/j.1582-4934.2011.01293.x
    [52] Lin PY, Sun L, Thibodeaux SR, et al. (2010) B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 185: 2747-2753. doi: 10.4049/jimmunol.1000496
    [53] Polanczyk MJ, Hopke C, Vandenbark AA, et al. (2006) Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 84: 370-378. doi: 10.1002/jnr.20881
    [54] Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nature Rev Immunol 16: 626-638. doi: 10.1038/nri.2016.90
    [55] Nance DM, Sanders VM (2007) Autonomic innervation and regulation of the immune system. Brain Behav Immun 21: 736-745. doi: 10.1016/j.bbi.2007.03.008
    [56] Priyanka HP, Pratap UP, Singh RV, et al. (2014) Estrogen modulates β2-adrenoceptor-induced cell-mediated and inflammatory immune responses through ER-α involving distinct intracellular signaling pathways, antioxidant enzymes, and nitric oxide. Cell Immunol 292: 1-8. doi: 10.1016/j.cellimm.2014.08.001
    [57] Priyanka HP, Krishnan HC, Singh RV, et al. (2013) Estrogen modulates in vitro T cell responses in a concentration- and receptor dependent manner: effects on intracellular molecular targets and antioxidant enzymes. Mol Immunol 56: 328-339. doi: 10.1016/j.molimm.2013.05.226
    [58] Pratap UP, Patil A, Sharma HR, et al. (2016) Estrogen-induced neuroprotective and anti-inflammatory effects are dependent on the brain areas of middle-aged female rats. Brain Res Bull 124: 238-253. doi: 10.1016/j.brainresbull.2016.05.015
    [59] Kale P, Mohanty A, Mishra M, et al. (2014) Estrogen modulates neural–immune interactions through intracellular signaling pathways and antioxidant enzyme activity in the spleen of middle-aged ovariectomized female rats. J Neuroimmunol 267: 7-15. doi: 10.1016/j.jneuroim.2013.11.003
    [60] Priyanka HP, Sharma U, Gopinath S, et al. (2013) Menstrual cycle and reproductive aging alters immune reactivity, NGF expression, antioxidant enzyme activities, and intracellular signaling pathways in the peripheral blood mononuclear cells of healthy women. Brain Behav Immun 32: 131-143. doi: 10.1016/j.bbi.2013.03.008
    [61] Ulrich-Lai YM, Herman JP (2009) Neural regulation of endocrine and autoimmune stress responses. Nat Rev Neurosci 10: 397-409. doi: 10.1038/nrn2647
    [62] Herman JP, Flak J, Jankord R (2008) Chronic stress plasticity in the hypothalamic paraventricular nucleus. Prog Brain Res 170: 353-364. doi: 10.1016/S0079-6123(08)00429-9
    [63] Iftikhar A, Islam M, Shepherd S, et al. (2021) Cancer and Stress: Does It Make a Difference to the Patient When These Two Challenges Collide? Cancers (Basel) 13: 163. doi: 10.3390/cancers13020163
    [64] Lin KT, Wang LH (2016) New dimension of glucocorticoids in cancer treatment. Steroids 111: 84-88. doi: 10.1016/j.steroids.2016.02.019
    [65] Antoni MH, Lutgendorf SK, Cole SW, et al. (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240-248. doi: 10.1038/nrc1820
    [66] Lutgendorf SK, Costanzo E, Siegel S (2007) Psychosocial influences in oncology: An expanded model of biobehavioral mechanisms. Psychoneuroimmunology New York, NY, USA: Academic Press, 869-895. doi: 10.1016/B978-012088576-3/50048-4
    [67] Xie H, Li B, Li L, et al. (2014) Association of increased circulating catecholamine and glucocorticoid levels with risk of psychological problems in oral neoplasm patients. PLoS One 9: e99179. doi: 10.1371/journal.pone.0099179
    [68] Lutgendorf SK, DeGeest K, Dahmoush L, et al. (2011) Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25: 250-255. doi: 10.1016/j.bbi.2010.10.012
    [69] Obeid EI, Conzen SD (2013) The role of adrenergic signaling in breast cancer biology. Cancer Biomark 13: 161-169. doi: 10.3233/CBM-130347
    [70] Mravec B, Horvathova L, Hunakova L (2020) Neurobiology of cancer: the role of β-adrenergic receptor signaling in various tumor environments. Int J Mol Sci 21: 7958. doi: 10.3390/ijms21217958
    [71] Thaker PH, Han LY, Kamat AA, et al. (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12: 939-944. doi: 10.1038/nm1447
    [72] Lin Q, Wang F, Yang R, et al. (2013) Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One 8: e61435. doi: 10.1371/journal.pone.0061435
    [73] Landen CN, Lin YG, Armaiz Pena GN, et al. (2007) Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67: 10389-10396. doi: 10.1158/0008-5472.CAN-07-0858
    [74] Shang ZJ, Liu K, Liang DF (2009) Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38: 371-376. doi: 10.1111/j.1600-0714.2008.00691.x
    [75] Saul AN, Oberyszyn TM, Daugherty C, et al. (2005) Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst 97: 1760-1767. doi: 10.1093/jnci/dji401
    [76] Ben-Eliyahu S, Page GG, Yirmiya R, et al. (1999) Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 80: 880-888. doi: 10.1002/(SICI)1097-0215(19990315)80:6<880::AID-IJC14>3.0.CO;2-Y
    [77] Ben-Eliyahu S, Yirmiya R, Liebeskind JC, et al. (1991) Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun 5: 193-205. doi: 10.1016/0889-1591(91)90016-4
    [78] Greenfeld K, Avraham R, Benish M, et al. (2007) Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 21: 503-513. doi: 10.1016/j.bbi.2006.12.006
    [79] Morris N, Moghaddam N, Tickle A, et al. (2018) The relationship between coping style and psychological distress in people with head and neck cancer: A systematic review. Psychooncology 27: 734-747. doi: 10.1002/pon.4509
    [80] Nogueira TE, Adorno M, Mendonça E, et al. (2018) Factors associated with the quality of life of subjects with facial disfigurement due to surgical treatment of head and neck cancer. Med Oral Patol Oral Cir Bucal 23: e132-e137.
    [81] Hagedoorn M, Molleman E (2006) Facial disfigurement in patients with head and neck cancer: the role of social self-efficacy. Health Psychol 25: 643-647. doi: 10.1037/0278-6133.25.5.643
    [82] Lackovicova L, Gaykema RP, Banovska L, et al. (2013) The time-course of hindbrain neuronal activity varies according to location during either intraperitoneal or subcutaneous tumor growth in rats: Single Fos and dual Fos/dopamine beta-hydroxylase immunohistochemistry. J Neuroimmunol 260: 37-46. doi: 10.1016/j.jneuroim.2013.04.010
    [83] Horvathova L, Tillinger A, Padova A, et al. (2020) Changes in gene expression in brain structures related to visceral sensation, autonomic functions, food intake, and cognition in melanoma-bearing mice. Eur J Neurosci 51: 2376-2393. doi: 10.1111/ejn.14661
    [84] Kin NW, Sanders VM (2006) It takes nerve to tell T and B cells what to do. J Leukocyte Biol 79: 1093-1104. doi: 10.1189/jlb.1105625
    [85] Straub RH (2004) Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci 25: 640-646. doi: 10.1016/j.tips.2004.10.007
    [86] Nance DM, Sanders VM (2007) Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav Immun 21: 736-745. doi: 10.1016/j.bbi.2007.03.008
    [87] Madden KS (2003) Catecholamines, sympathetic innervation, and immunity. Brain Behav Immun 17: S5-10. doi: 10.1016/S0889-1591(02)00059-4
    [88] ThyagaRajan S, Felten DL (2002) Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. Mech Ageing Dev 123: 1065-1079. doi: 10.1016/S0047-6374(01)00390-6
    [89] Pratap U, Hima L, Kannan T, et al. (2020) Sex-Based Differences in the Cytokine Production and Intracellular Signaling Pathways in Patients With Rheumatoid Arthritis. Arch Rheumatol 35: 545-557. doi: 10.46497/ArchRheumatol.2020.7481
    [90] Hima L, Patel M, Kannan T, et al. (2020) Age-associated decline in neural, endocrine, and immune responses in men and women: Involvement of intracellular signaling pathways. J Neuroimmunol 345: 577290. doi: 10.1016/j.jneuroim.2020.577290
    [91] Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10. doi: 10.1016/j.immuni.2013.07.012
    [92] Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570. doi: 10.1126/science.1203486
    [93] Sanders VM (1995) The role of adrenoceptor-mediated signals in the modulation of lymphocyte function. Adv Neuroimmunol 5: 283-298. doi: 10.1016/0960-5428(95)00019-X
    [94] Madden KS, Felten DL (1995) Experimental basis for neural-immune interactions. Physiol Rev 75: 77-106. doi: 10.1152/physrev.1995.75.1.77
    [95] Madden KS (2003) Catecholamines, sympathetic innervation, and immunity. Brain Behav Immun 17: S5-10. doi: 10.1016/S0889-1591(02)00059-4
    [96] Callahan TA, Moynihan JA (2002) The effects of chemical sympathectomy on T-cell cytokine responses are not mediated by altered peritoneal exudate cell function or an inflammatory response. Brain Behav Immun 16: 33-45. doi: 10.1006/brbi.2000.0618
    [97] Madden KS, Felten SY, Felten DL, et al. (1989) Sympathetic neural modulation of the immune system. I. Depression of T cell immunity in vivo and vitro following chemical sympathectomy. Brain Behav Immun 3: 72-89. doi: 10.1016/0889-1591(89)90007-X
    [98] Alaniz RC, Thomas SA, Perez-Melgosa M, et al. (1999) Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci U S A 96: 2274-2278. doi: 10.1073/pnas.96.5.2274
    [99] Pongratz G, McAlees JW, Conrad DH, et al. (2006) The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner. J Immunol 177: 2926-2938. doi: 10.4049/jimmunol.177.5.2926
    [100] Chen F, Zhuang X, Lin L, et al. (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13: 45. doi: 10.1186/s12916-015-0278-7
    [101] Wang M, Zhao J, Zhang L, et al. (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8: 761-773. doi: 10.7150/jca.17648
    [102] Del Prete A, Schioppa T, Tiberio L, et al. (2017) Leukocyte trafficking in tumor microenvironment. Curr Opin Pharmacol 35: 40-47. doi: 10.1016/j.coph.2017.05.004
    [103] Jiang Y, Li Y, Zhu B (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6: e1792. doi: 10.1038/cddis.2015.162
    [104] Maimela NR, Liu S, Zhang Y (2019) Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J 17: 1-13. doi: 10.1016/j.csbj.2018.11.004
    [105] Zhang Z, Liu S, Zhang B, et al. (2020) T Cell Dysfunction and Exhaustion in Cancer. Front Cell Dev Biol 8: 17. doi: 10.3389/fcell.2020.00017
    [106] Gonzalez H, Robles I, Werb Z (2018) Innate and acquired immune surveillance in the postdissemination phase of metastasis. FEBS J 285: 654-664. doi: 10.1111/febs.14325
    [107] Komohara Y, Fujiwara Y, Ohnishi K, et al. (2016) Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Delivery Rev 99: 180-185. doi: 10.1016/j.addr.2015.11.009
    [108] Mantovani A, Marchesi F, Malesci A, et al. (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14: 399-416. doi: 10.1038/nrclinonc.2016.217
    [109] Linde N, Lederle W, Depner S, et al. (2012) Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol 227: 17-28. doi: 10.1002/path.3989
    [110] Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105: 1-8. doi: 10.1111/cas.12314
    [111] Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27: 462-472. doi: 10.1016/j.ccell.2015.02.015
    [112] Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41: 49-61. doi: 10.1016/j.immuni.2014.06.010
    [113] Long KB, Gladney WL, Tooker GM, et al. (2016) IFN-γ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discov 6: 400-413. doi: 10.1158/2159-8290.CD-15-1032
    [114] Muz B, de la Puente P, Azab F, et al. (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 3: 83-92. doi: 10.2147/HP.S93413
    [115] Zhang CC, Sadek HA (2014) Hypoxia and metabolic properties of hematopoietic stem cells. Antioxid Redox Signal 20: 1891-1901. doi: 10.1089/ars.2012.5019
    [116] Henze AT, Mazzone M (2016) The impact of hypoxia on tumor-associated macrophages. J Clin Invest 126: 3672-3679. doi: 10.1172/JCI84427
    [117] Chen P, Zuo H, Xiong H, et al. (2017) Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci 114: 580-585. doi: 10.1073/pnas.1614035114
    [118] Albo D, Akay CL, Marshall CL, et al. (2011) Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes. Cancer 117: 4834-4845. doi: 10.1002/cncr.26117
    [119] Kamiya A, Hiyama T, Fujimura A, et al. (2021) Sympathetic and parasympathetic innervation in cancer: therapeutic implications. Clin Auton Res 31: 165-178. doi: 10.1007/s10286-020-00724-y
    [120] Ceyhan GO, Schäfer KH, Kerscher AG, et al. (2010) Nerve growth factor and artemin are paracrine mediators of pancreatic neuropathy in pancreatic adenocarcinoma. Ann Surg 251: 923-931. doi: 10.1097/SLA.0b013e3181d974d4
    [121] Zhao CM, Hayakawa Y, Kodama Y, et al. (2014) Denervation suppresses gastric tumorigenesis. Sci Transl Med 6: 250ra115. doi: 10.1126/scitranslmed.3009569
    [122] Liebig C, Ayala G, Wilks JA, et al. (2009) Perineural invasion in cancer: a review of the literature. Cancer 115: 3379-3391. doi: 10.1002/cncr.24396
    [123] Dai H, Li R, Wheeler T, et al. (2007) Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol 38: 299-307. doi: 10.1016/j.humpath.2006.08.002
    [124] Liebig C, Ayala G, Wilks J, et al. (2009) Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 27: 5131-5137. doi: 10.1200/JCO.2009.22.4949
    [125] Conceição F, Sousa DM, Paredes J, et al. (2021) Sympathetic activity in breast cancer and metastasis: partners in crime. Bone Res 9: 9. doi: 10.1038/s41413-021-00137-1
    [126] Mauffrey P, Tchitchek N, Barroca V, et al. (2019) Progenitors from the central nervous system drive neurogenesis in cancer. Nature 569: 672-678. doi: 10.1038/s41586-019-1219-y
    [127] Ruscica M, Dozio E, Motta M, et al. (2007) Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 28: 426-434. doi: 10.1016/j.peptides.2006.08.045
    [128] Hayakawa Y, Sakitani K, Konishi M, et al. (2017) Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. Cancer Cell 31: 21-34. doi: 10.1016/j.ccell.2016.11.005
    [129] Barabutis N (2021) Growth Hormone Releasing Hormone in Endothelial Barrier Function. Trends Endocrinol Metab 32: 338-340. doi: 10.1016/j.tem.2021.03.001
    [130] ThyagaRajan S, Madden KS, Kalvass JC, et al. (1998) L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats. J Neuroimmunol 92: 9-21. doi: 10.1016/S0165-5728(98)00039-3
    [131] Zumoff B (1998) Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med 217: 30-37. doi: 10.3181/00379727-217-44202
    [132] Hollingsworth AB, Lerner MR, Lightfoot SA, et al. (1998) Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res Treat 47: 63-70. doi: 10.1023/A:1005872132373
    [133] Sun G, Wu L, Sun G, et al. (2021) WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Manag Res 13: 2483-2498. doi: 10.2147/CMAR.S289819
    [134] Schlange T, Matsuda Y, Lienhard S, et al. (2007) Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 9: R63. doi: 10.1186/bcr1769
    [135] Sun X, Bernhardt SM, Glynn DJ, et al. (2021) Attenuated TGFB signalling in macrophages decreases susceptibility to DMBA-induced mammary cancer in mice. Breast Cancer Res 23: 39. doi: 10.1186/s13058-021-01417-8
    [136] Heasley L (2001) Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20: 1563-1569. doi: 10.1038/sj.onc.1204183
    [137] Cuttitta F, Carney DN, Mulshine J, et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316: 823-826. doi: 10.1038/316823a0
    [138] Moody TW, Pert CB, Gazdar AF, et al. (1981) Neurotensin is produced by and secreted from classic small cell lung cancer cells. Science 214: 1246-1248. doi: 10.1126/science.6272398
    [139] Cardona C, Rabbitts PH, Spindel ER, et al. (1991) Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res 51: 5205-5211.
    [140] Sun B, Halmos G, Schally AV, et al. (2000) Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 42: 295-303. doi: 10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B
    [141] Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159.
    [142] Moody TW, Pert CB, Gazdar AF, et al. (1981) Neurotensin is produced by and secreted from classic small cell lung cancer cells. Science 214: 1246-1248. doi: 10.1126/science.6272398
    [143] Goetze JP, Nielsen FC, Burcharth F, et al. (2000) Closing the gastrin loop in pancreatic carcinoma: Co-expression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88: 2487-2494. doi: 10.1002/1097-0142(20000601)88:11<2487::AID-CNCR9>3.0.CO;2-E
    [144] Blackmore M, Hirst B (1992) Autocrine stimulation of growth of AR4-2J rat pancreatic tumour cells by gastrin. Br J Cancer 66: 32-38. doi: 10.1038/bjc.1992.212
    [145] Smith JP, Liu G, Soundararajan V, et al. (1994) Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 266: R277-283.
    [146] Seethalakshmi L, Mitra SP, Dobner PR, et al. (1997) Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 31: 183-192. doi: 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M
    [147] Kawaguchi K, Sakurai M, Yamamoto Y, et al. (2019) Alteration of specific cytokine expression patterns in patients with breast cancer. Sci Rep 9: 2924. doi: 10.1038/s41598-019-39476-9
    [148] Smyth MJ, Cretney E, Kershaw MH, et al. (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202: 275-293. doi: 10.1111/j.0105-2896.2004.00199.x
    [149] Wang X, Lin Y (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29: 1275-1288. doi: 10.1111/j.1745-7254.2008.00889.x
    [150] Ohri CM, Shikotra A, Green RH, et al. (2010) Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 10: 323. doi: 10.1186/1471-2407-10-323
    [151] Woo CH, Eom YW, Yoo MH, et al. (2000) Tumor necrosis factor-α generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem 275: 32357-32362. doi: 10.1074/jbc.M005638200
    [152] Suganuma M, Watanabe T, Yamaguchi K, et al. (2012) Human gastric cancer development with TNF-α-inducing protein secreted from Helicobacter pylori. Cancer Lett 322: 133-138. doi: 10.1016/j.canlet.2012.03.027
    [153] Cai X, Cao C, Li J, et al. (2017) Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1. Oncotarget 8: 58338-58352. doi: 10.18632/oncotarget.16873
    [154] Fiorentino DF, Bond MW, Mosmann TR (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095. doi: 10.1084/jem.170.6.2081
    [155] Ikeguchi M, Hatada T, Yamamoto M, et al. (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12: 95-100. doi: 10.1007/s10120-009-0509-8
    [156] Hassuneh MR, Nagarkatti M, Nagarkatti PS (2013) Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma. Leuk Lymphoma 54: 827-834. doi: 10.3109/10428194.2012.726721
    [157] Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512. doi: 10.1016/j.ejca.2005.08.016
    [158] Kim SY, Kang JW, Song X, et al. (2013) Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signaling 25: 961-969. doi: 10.1016/j.cellsig.2013.01.007
    [159] Mravec B, Horvathova L, Cernackova A (2019) Hypothalamic Inflammation at a Crossroad of Somatic Diseases. Cell Mol Neurobiol 39: 11-29. doi: 10.1007/s10571-018-0631-4
    [160] Morrison CD, Parvani JG, Schiemann WP (2013) The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett 341: 30-40. doi: 10.1016/j.canlet.2013.02.048
    [161] Bierie B, Moses HL (2006) TGF-β and cancer. Cytokine Growth Factor Rev 17: 29-40. doi: 10.1016/j.cytogfr.2005.09.006
    [162] Levy L, Hill CS (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58. doi: 10.1016/j.cytogfr.2005.09.009
  • This article has been cited by:

    1. Zhenghui Li, Liming Chen, Hao Dong, What are bitcoin market reactions to its-related events?, 2021, 73, 10590560, 1, 10.1016/j.iref.2020.12.020
    2. Tinghui Li, Xue Li, Gaoke Liao, Business cycles and energy intensity. Evidence from emerging economies, 2022, 22, 22148450, 560, 10.1016/j.bir.2021.07.005
    3. Yaya Su, Zhenghui Li, Cunyi Yang, Spatial Interaction Spillover Effects between Digital Financial Technology and Urban Ecological Efficiency in China: An Empirical Study Based on Spatial Simultaneous Equations, 2021, 18, 1660-4601, 8535, 10.3390/ijerph18168535
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3782) PDF downloads(103) Cited by(0)

Figures and Tables

Figures(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog